Caris Life Sciences Advances Precision Oncology with New AI Insights Predicting Brain Metastases Risk in Breast and Lung Cancer

Rhea-AI Summary

Caris Life Sciences (NASDAQ: CAI) added two proprietary Caris AI Insights signatures predicting brain metastases risk in breast cancer and non-small cell lung cancer (NSCLC), bringing its total to seven.

The signatures were trained on 12,994 NSCLC and 3,371 breast cases and use WES/WTS data; MI Cancer Seek orders include the report at no extra cost. Caris reports its multimodal dataset exceeds 500,000 patients tested and notes an ongoing study with the Caris Precision Oncology Alliance to highlight the risk‑prediction approach.

Positive

• Two new AI signatures added for brain metastases risk in breast cancer and NSCLC
• Total of seven proprietary Caris AI insights available to customers
• Trained on 12,994 NSCLC and 3,371 breast cases with matched outcomes
• Dataset exceeds 500,000 patients with WES/WTS, imaging and longitudinal data
• MI Cancer Seek orders include the report at no additional cost

Negative

• Breast signature trained on 3,371 cases, a smaller training cohort than NSCLC
• Clinical validation ongoing: a study with the Caris POA is in progress (no final results yet)

Key Figures

NSCLC training set: 12,994 cases Breast training set: 3,371 cases WES/WTS patients: over 500,000 patients +5 more

8 metrics

NSCLC training set 12,994 cases NSCLC cohort used to train brain metastases risk signatures

Breast training set 3,371 cases Breast cancer cohort used to train brain metastases risk signatures

WES/WTS patients over 500,000 patients Patients tested with WES and WTS feeding CodeAI multimodal dataset

Oncology cases sequenced over 1,000,000 cases Total oncology sequencing volume as of Dec 31, 2025

Ordering physicians over 6,000 physicians Clinicians using Caris platforms reported in 10-K filing

MI Cancer Seek FDA approval November 2024 First WES/WTS-based tissue assay with CDx indications

Current share price $18.53 Price before market reaction to March 26, 2026 AI announcement

52-week range $17.15 – $56.22 Current level about 8.05% above low and 67.04% below high

Market Reality Check

Price: $18.32 Vol: Volume 1,434,846 is about...

low vol

$18.32 Last Close

Volume Volume 1,434,846 is about 50% of the 2,858,376 share 20-day average, indicating muted trading interest ahead of this AI announcement. low

Technical Shares at 18.53 are trading below the 200-day moving average of 28.57, reflecting a longer-term downtrend into this news.

Peers on Argus

While CAI fell about 3.53%, key biotech peers like MDGL (+2.93%), MRNA (+1.85%),...

While CAI fell about 3.53%, key biotech peers like MDGL (+2.93%), MRNA (+1.85%), ROIV (+0.40%), HALO (+0.73%) and VRNA (+0.06%) traded higher, pointing to stock-specific pressure rather than a sector move.

Previous AI Reports

5 past events · Latest: Mar 16 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 16	New AI signature	Positive	+3.5%	Launched AI signature predicting platinum resistance in HGSOC via WES/WTS data.
Mar 09	New AI signature	Positive	+2.2%	Introduced AI signature to guide first-line and de-escalation in pancreatic cancer.
Feb 24	AI breast signature	Positive	+3.2%	Added AI breast cancer signature predicting capecitabine response using WES/WTS data.
Aug 06	AI outcomes study	Positive	-4.5%	Published study showing AI-positive breast patients had better survival on checkpoint therapy.
Aug 05	AI tissue-of-origin	Positive	+2.8%	Reported best-in-class AI tissue-of-origin accuracy and impact on misdiagnosed patients.

Pattern Detected

AI-tag announcements have generally triggered positive price reactions for CAI, with four gains and one notable negative reaction in the past, suggesting investors often reward new AI capabilities but remain selective.

Recent Company History

Over recent months, CAI has repeatedly expanded its AI-driven precision oncology tools. Prior AI-tag events added signatures for ovarian, pancreatic and breast cancer, all tied to MI Cancer Seek, which received FDA approval in November 2024. These updates typically produced gains between about 2–3.5%, except for one AI study in August 2025 that saw a -4.46% move. Today’s new brain metastases risk signatures extend that same AI Insights strategy across additional tumor types.

Historical Comparison

+1.4% avg move · Past AI-tag announcements for CAI saw an average move of 1.43%, mainly positive. Today’s new brain m...

AI

+1.4%

Average Historical Move AI

Past AI-tag announcements for CAI saw an average move of 1.43%, mainly positive. Today’s new brain metastases risk signatures continue the pattern of incremental AI enhancements across major tumor types.

AI-tag history shows a progression from broad tissue-of-origin and outcomes models to cancer-specific therapy guidance in pancreatic, ovarian and breast cancer, now extending into brain metastases risk for breast and NSCLC.

Market Pulse Summary

This announcement adds two AI signatures predicting brain metastases risk in breast and NSCLC, expan...

Analysis

This announcement adds two AI signatures predicting brain metastases risk in breast and NSCLC, expanding CAI’s Caris AI Insights portfolio to seven tools and leveraging a dataset of over 500,000 WES/WTS-tested patients. Historically, AI-tag news has often produced modest positive moves around 1.43%. Investors may track clinical study readouts, integration into MI Cancer Seek, and utilization trends against a backdrop of shares trading well below the 52-week high and 200-day MA.

Key Terms

brain metastases, non-small cell lung cancer (NSCLC), whole exome sequencing (WES), whole transcriptome sequencing (WTS), +2 more

6 terms

brain metastases medical

"These signatures assess the risk of patients developing brain metastases in breast and lung cancer."

Cancer cells that have spread from another part of the body to the brain, forming new tumors there. Think of it like weeds from one garden taking root in another; the behavior and treatment needs can change significantly once cancer reaches the brain. For investors, brain metastases matter because they often drive different clinical trial designs, higher healthcare costs, and urgent demand for effective therapies, all of which can materially affect a biotech or healthcare company’s prospects.

non-small cell lung cancer (NSCLC) medical

"The novel Caris signatures for breast cancer and non-small cell lung cancer (NSCLC) predict a patient's risk"

A common group of lung cancers that arise from the lungs’ cell lining and grow in ways different from the faster-spreading “small cell” form; think of it as several related varieties of the same illness rather than one single disease. It matters to investors because diagnosis rates, new drugs, diagnostic tests, and clinical trial results for these cancers can drive large, sustained revenue opportunities and regulatory decisions that materially affect healthcare and biotech company valuations.

whole exome sequencing (WES) medical

"over half a million patients tested with Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)"

Whole exome sequencing (WES) reads the portions of a person’s DNA that code for proteins — about the most critical pages in the body’s instruction manual. By focusing on these protein-making sections rather than the entire genome, WES helps identify changes that can cause disease, guide diagnosis, or point to targets for drugs. Investors care because WES can speed discovery, reduce clinical uncertainty, and create clearer paths to diagnostic tests and targeted treatments that drive commercial value.

whole transcriptome sequencing (WTS) medical

"over half a million patients tested with Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)"

Whole transcriptome sequencing (WTS) is a lab method that reads all the RNA messages inside a cell or tissue to show which genes are turned on or off, similar to collecting every email in an office to understand what tasks are being done. For investors, WTS matters because it can reveal disease mechanisms, identify drug targets or biomarkers, and improve patient selection or diagnostic tests—information that can change the commercial potential of therapies and diagnostics.

companion diagnostic (CDx) regulatory

"assay is the first and only simultaneous WES and WTS-based assay with FDA-approved companion diagnostic (CDx) indications"

A companion diagnostic (CDx) is a medical test designed to identify which patients are likely to benefit from, or be harmed by, a specific drug or therapy—think of it as a key that shows which locks a particular medicine can open. For investors, a CDx matters because it shapes how many patients can use the drug, affects regulatory approval and reimbursement odds, and reduces commercial and clinical risk by targeting treatment to the right people.

molecular profiling medical

"for molecular profiling of solid tumors."

Molecular profiling is a laboratory analysis that reads a patient’s disease at the level of genes, proteins or other molecules to reveal its specific characteristics—think of it as reading the instruction manual for a tumor or condition. For investors, it matters because the results guide which targeted treatments, diagnostics or tests will be used, shaping clinical demand, regulatory approval paths and potential revenue for companies developing precision medicines and companion tests.

AI-generated analysis. Not financial advice.

Caris AI Insights are proprietary algorithms only available to Caris Life Sciences customers and not achievable through small panels

IRVING, Texas, March 26, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced the addition of two new Caris AI Insights™ signatures included in the Caris Molecular Tumor Board Report. These signatures assess the risk of patients developing brain metastases in breast and lung cancer. The addition of these two signatures brings the total number of proprietary Caris AI insights to seven, providing deeper insights to physicians and patients. This report, available upon request when ordering MI Cancer Seek® at no additional cost, provides clinicians with additional insights across all tumor types with specific algorithms for treatment decisions for colon, breast, ovarian, pancreatic and lung cancer.

Caris Life Sciences is accelerating the future of precision oncology by utilizing the world's most complete multimodal real‑world dataset through its proprietary CodeAI™ platform, now exceeding over half a million patients tested with Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS), H&E and IHC images with longitudinal follow-up clinical data. The novel Caris signatures for breast cancer and non-small cell lung cancer (NSCLC) predict a patient's risk of brain metastases. Brain metastases are a common and serious complication for a subset of breast and lung cancer patients, so identifying the risk for this type of complication early is a meaningful step to support more informed clinical decision‑making.

"Insights from these proprietary Caris AI signatures give us a forward-looking view of which patients may be at elevated risk for brain metastases, allowing us to help guide clinicians to shift from passive surveillance to more proactive monitoring," said Caris President David Spetzler, MS, PhD, MBA. "Advanced clinical AI tools like Caris AI Insights are helping future-proof cancer care by integrating molecular intelligence into everyday decision making, so that we can personalize care earlier and with greater precision."

The brain metastases signatures were trained on a large set of 12,994 NSCLC cases and 3,371 breast cancer cases with matched survival outcomes. The signatures generate a personalized predictive score using each patient's WES and WTS data. Results are visualized as Kaplan‑Meier curves, providing clinicians with an intuitive view of the likelihood and rate of brain metastasis development based on the patient's molecular profile.

Caris received FDA approval in November 2024 for MI Cancer Seek. This tissue-based assay is the first and only simultaneous WES and WTS-based assay with FDA-approved companion diagnostic (CDx) indications for molecular profiling of solid tumors.

A study is in progress with collaborators of the Caris Precision Oncology Alliance® (POA®) to highlight how risk prediction for brain metastases in breast and lung cancer patients is achieved using Caris AI Insights. The Caris POA is a global network of leading cancer centers and research groups that collaborate to advance precision oncology and biomarker-driven research. 

About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.

Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law. 

Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606 

View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-advances-precision-oncology-with-new-ai-insights-predicting-brain-metastases-risk-in-breast-and-lung-cancer-302725638.html

SOURCE Caris Life Sciences

FAQ

What do the new Caris AI Insights for brain metastases predict for CAI patients?

They predict individualized risk of brain metastases using molecular data and generate a personalized score. According to the company, scores use each patient's WES and WTS data and are visualized with Kaplan‑Meier curves to show likelihood and timing of brain metastasis.

How large were the training datasets for the Caris brain metastases signatures (CAI)?

The NSCLC signature was trained on 12,994 cases and the breast signature on 3,371 cases. According to the company, both datasets included matched survival outcomes used to build the predictive models.

Is the Caris brain metastases report included with MI Cancer Seek orders for CAI?

Yes — the Caris AI Insights report is available upon request at no additional cost when ordering MI Cancer Seek. According to the company, clinicians receive the report alongside other molecular profiling results.

Does Caris have regulatory clearance for MI Cancer Seek (CAI) and its molecular assays?

Yes — MI Cancer Seek received FDA approval in November 2024 as a tissue‑based WES/WTS assay with companion diagnostic indications. According to the company, this approval covers the simultaneous WES and WTS–based assay.

Are the Caris brain metastases predictions clinically validated for CAI patients?

A validation study is currently in progress with collaborators in the Caris Precision Oncology Alliance. According to the company, the study aims to highlight how risk prediction is achieved but final study results are not yet reported.